This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RENB Lunai Bioworks (RENB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Lunai Bioworks Stock (NASDAQ:RENB) Get Lunai Bioworks alerts:Sign Up Key Stats Today's Range$1.13▼$1.4350-Day Range$1.30▼$2.3852-Week Range$0.12▼$1.43Volume880,400 shsAverage Volume2.93 million shsMarket Capitalization$250.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. Read More Receive RENB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lunai Bioworks and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RENB Stock News HeadlinesLunai Bioworks Furloughs Staff Amid Liquidity ConstraintsMarch 5, 2026 | tipranks.comLunai Bioworks Faces Nasdaq Delisting, Hearing ScheduledFebruary 23, 2026 | tipranks.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.June 10 at 1:00 AM | InvestorPlace (Ad)Lunai Bioworks Secures $3.1M in Private PlacementNovember 25, 2025 | tipranks.comLunai Bioworks announces early results from AI-based platformOctober 31, 2025 | msn.comLunai Bioworks unveils new corporate identitySeptember 30, 2025 | msn.comLunai Bioworks advances biomarker discovery preclinical program in Parkinson’sSeptember 25, 2025 | msn.comLunai Bioworks Inc.: Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock SplitSeptember 25, 2025 | finanznachrichten.deSee More Headlines RENB Stock Analysis - Frequently Asked Questions How were Lunai Bioworks' earnings last quarter? Lunai Bioworks Inc. (NASDAQ:RENB) posted its quarterly earnings data on Wednesday, February, 19th. The company reported ($0.20) earnings per share (EPS) for the quarter. When did Lunai Bioworks' stock split? Shares of Lunai Bioworks reverse split before market open on Monday, September 29th 2025.The 1-10 reverse split was announced on Wednesday, September 24th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Lunai Bioworks IPO? Lunai Bioworks (RENB) raised $12 million in an IPO on the week of December 10th 2018. The company issued 2,400,000 shares at a price of $5.00 per share. What other stocks do shareholders of Lunai Bioworks own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lunai Bioworks investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW). Company Calendar Last Earnings2/19/2025Today6/10/2026Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RENB CIK1527728 Webwww.enochianbio.com Phone305-918-1980FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-60.38% Return on Assets-47.04% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.89 per share Price / Book1.73Miscellaneous Outstanding Shares162,390,000Free Float171,258,000Market Cap$250.24 million OptionableOptionable Beta0.54 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:RENB) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredImportant SpaceX PREDICTIONThe biggest IPO in stock market history could go live as soon as June 12th — but trading legend Jon Najarian s...Banyan Hill Publishing | SponsoredHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lunai Bioworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lunai Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
